Chimeric antigen receptor (CAR) T cells are efficacious in patients with B cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T cell CD3 signaling complex. The TCAR mediated high antigen sensitivity and potent antigen-specific T cell effector functions in short-term in vitro assays. Both persistence and functionality of TCAR T cells were augmented by provision of costimulatory signals, which improved proliferation in vitro and in vivo. Combination with a nanoparticulate RNA vaccine (CARVac), developed for in vivo expansion of CAR T cells, promoted tightly controlled expansion, survival and anti-tumor efficacy of TCAR T cells in vivo.

This content is only available via PDF.

Article PDF first page preview

Article PDF first page preview